ANGICYTE™
VascVersa's ANGICYTE™ Technology provides a revolutionary Cell Therapy for blood vessel regeneration. It stimulates new blood vessel formation leading to improved blood supply & long term healing. This pipeline technology has the potential to be used for a number of ischaemic diseases. Our first product will provide a new therapeutic solution for the active wound care market.
JUNE 24
VascVersa attend the International Society for Cell & Gene Therapy 2024
Both Christina and Stuart were delighted to attend ISCT 2024 in Vancouver. It was fantastic to have the opportunity to connect with experts in the cell and gene therapy field and ...
JUNE 24
Christina takes part in Region City Deal roundtable discussion
Christina represented VascVersa at the panel discussion. It was great to showcase VascVersa and give the audience an insight into...
MAY 24
Fiona wins a C-TRIC funding competition
Fiona was successful in her application for the C-TRIC single-cell competition. Winning this competition funds a multiomic analysis study worth £10K...
Latest News
Cell therapies such as ANGICYTE™ technology that treat disease by regenerating tissue are at the forefront of medicine and are recognised as one of the world’s leading technologies that drive innovation and promote productivity and economic growth.
Our Mission
At VascVersa, we are committed to developing innovative regenerative medicine, to deliver a profound improvement to the lives of many individuals suffering from debilitating ischaemic diseases. In doing so we will address the urgent need for new treatments to repair damaged blood vessels and revitalise tissue.
Research & Drug Discovery
We have developed robust and consistent methodology to generate valuable human vascular reparative cells from a small sample of blood. Our unique method of generation produces highly pure and potent populations of ANGICYTE™ cells.
ANGICYTE™ creates stable blood vessels in vitro and in vivo. It can also provide a vital source of blood vessel cells for researchers studying angiogenesis or can be used to discover new drug therapies for cancer.